A patient with HIV (Human Immunodeficiency Virus) has a CD4 count of 180 cells/mm². Which prophylactic therapy is priority?

When a patient with HIV has a CD4 count below 200 cells/mm³, the immune system is severely compromised and the risk of opportunistic infections rises dramatically. Pneumocystis jirovecii pneumonia (PCP) is the most common and life-threatening opportunistic infection in this population, and guidelines recommend initiating prophylaxis — typically with trimethoprim-sulfamethoxazole (TMP-SMX) — once the CD4 count falls below 200 cells/mm³. This patient's count of 180 cells/mm³ clearly meets that threshold, making PCP prevention the priority intervention. Influenza vaccination is important but is not the priority prophylactic measure at this CD4 level, and it does not address the most immediate opportunistic infection risk. Stating that no intervention is indicated is incorrect and potentially dangerous given the degree of immunosuppression. Stopping antiretroviral therapy would worsen immune decline, increase viral load, and further increase infection risk — the opposite of what is needed. The clinical principle here is that CD4 count-driven prophylaxis is a cornerstone of HIV management, and PCP prophylaxis is the first and most critical threshold to address, taking priority over other considerations in this scenario.